So much for a quiet summer. ATV’s portfolio companies have been busy making headlines in major media outlets in recent weeks with news of strategic acquisitions, breakthrough clinical data published in prominent medical and scientific journals, FDA clearance of revolutionary new treatments, significant investments from strategic investors, and other milestone achievements.

ATV, when not working with portfolio companies to support these milestones, has been actively identifying and investing in innovative emerging companies, often in the earliest stages of development.  “Working with a company in its formative stages, especially those led by a founder or team we’ve worked with previously, is particularly rewarding,“ said Mike Carusi, ATV General Partner .  “Getting in at the earliest stages of company development enables us to play a greater role in lending our expertise, experience, and contacts, in addition to funding.”

ATV has completed 22 financings to date in 2010, including new investments in Altura Medical, Calithera Biosciences, Catabasis Pharmaceuticals and, most recently, Actifio.

Following is a summary of portfolio company news highlights.  For a more complete summary of company news and media coverage, or to read the full articles referenced below, visit



Harmonic (NASDAQ: HLIT), a leading provider of broadcast and on-demand video delivery solutions, completed its acquisition of Omneon this month, representing an enterprise value of approximately $273 million.

In July, Illumina (NASDAQ: ILMN), the leading maker of high-speed gene sequencing instruments,  announced its acquisition of Helixis for $70 million in cash up front, plus another $35 million in contingent considerations.  The acquisition is aimed at putting low-cost genetic analysis systems on every biologist’s benchtop, analogous to how the PC replaced the mainframe computer.  ATV and Domain had led the Series A round.

Plexxikon made major headlines this month with news of its Phase 1 data - demonstrating an 81 percent response rate in metastatic melanoma patients - published in The New England Journal of Medicine and Nature, premier international medical and science journals. News of these reports ran on NBC Nightly News, in The Wall Street Journal and many other major media outlets around the globe, including a feature article in The Sunday New York Times, Sept. 19, entitled, "New Drugs Stir Debate on Rules of Clinical Trials."

Earlier this month, Zeltiq received clearance from the U.S. Food and Drug Administration (FDA) for CoolScultping ™, its revolutionary procedure that has been found to safely eliminate an average of 20 percent of fat in treated areas.  As a result, Zeltiq has been featured on ABC’s Good Morning America, in The Wall Street Journal, and in many other media outlets.

Acceleron Pharma received FDA Fast Track designation in August for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. The company also announced a partnership with Shire PLC, in which Shire will pay $45 million up front to Acceleron to co-develop and market potential treatments for muscular and neuromuscular disorders.

Rive Technology announced that it has entered into an agreement with W.R. Grace & Co. (NYSE: GRA).  Rive and Grace will jointly develop and commercialize Rive’s zeolite technology for use in catalysts for fluid catalytic cracking (FCC) processes within a petroleum refinery.

Portola Pharmaceuticals said its partner Novartis AG will begin final-stage testing of its antiplatelet drug, elinogrel, in the first quarter of 2011. Phase 2 results showed that an intravenous and oral elinogrel regimen provided more rapid and greater antiplatelet activity than clopidogrel (Plavix®) without a significant increase in the risk of bleeding. 

Five Prime Therapeutics recently announced a strategic partnership with GlaxoSmithKline, through which it secured $15 million in an upfront fee, plus $124 million in potential milestone payments, to screen various combinations of biological targets and drug candidates for skeletal muscle disorders.

Three ATV portfolio companies – Acceleron, Catabasis, and Plexxikon – were recently featured among Fierce Biotech’s ‘Fierce 15,’ list of the 15 most promising biotech startups for 2010.

CaliSolar was awarded a $5 million loan by the California Energy Commission to expand the manufacture of its high performance photovoltaic cells. The company also announced the appointment of Sandra Beach Lin as its new CEO.

AltaRock was featured in a recent The Wall Street Journal story entitled, “Not Just a Lot of Hot Air” about the resurgence in geothermal energy, spurred by new technology and government funding.

[X+1] was featured in a page one The Wall Street Journal article last month entitled, “On the Web's Cutting Edge, Anonymity in Name Only,” on the burgeoning digital marketing space.  The company was also featured on an associated WSJ news video.


Altura Medical - an early stage medical device company focused on innovative devices and methods for the percutaneous treatment of abdominal aortic aneurysms.  The company, founded by ATV VII portfolio company TranS1 (NASDAQ:TSON) founders Dr. Andy Cragg and George Wallace, raised $20 million in a Series A financing.

Calithera Biosciences - a Bay Area biotech company focused on activation therapeutics.  The company is developing novel small molecule cancer drugs that activate caspases, the enzymes that control programmed cell death.  The company raised $40 million in Series A financing and was founded by Susan Molienaux, former CEO of Proteolix, an ATV portfolio company acquired by ONYX Pharmaceuticals (NASDAQ: ONXX) last November.

Actifio – a leader in data management virtualization (DMV), delivering unified data protection, disaster recovery and business continuity across the data lifecycle for virtual and physical IT environments.   The company last week announced that it raised $16 million in its second round of venture financing, led by ATV.  Actifio’s Ash Ashutosh and David Chang were also co-founders of App IQ, a previous ATV portfolio company   acquired by HP. 

For a more complete summary of these and other portfolio company highlights, or to read the full articles mentioned above, visit